CBER/CDER Merger Is One Topic Of Erbitux Discussions In House Cmte.
Executive Summary
The House Energy & Commerce Committee investigation of the Erbitux review could re-energize proposals to combine FDA's drugs and biologics centers
You may also be interested in...
FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
FDA Oncology Therapeutics Office Planned; Drug, Biologics Units Will Merge
FDA is understood to be finalizing a plan for a new office of cancer therapeutics that would merge the current drug and biologics review groups within the Center for Drug Evaluation & Research's Office of New Drugs
Erbitux Hearing May Feature FDA Reviewer Communication Policies
The House Energy & Commerce Committee's Oct. 10 follow-up hearing on the Erbitux (cetuximab) BLA may serve as a venue to discuss FDA's internal policy on communication between reviewers and sponsors over pending applications